Dyadic International Appoints Chief Accounting Officer
March 15 2018 - 4:30PM
JUPITER, Fla., March 15, 2018 (GLOBE NEWSWIRE)
-- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), today
announced that Chief Financial Officer Thomas L.
Dubinski
will be on a medical leave of absence, effectively
immediately. In Mr. Dubinski’s absence, other executive officers
will assume many of Mr. Dubinski’s duties while remaining in their
current positions. Ping W. Rawson, the Company’s Director of
Financial Reporting since June 2016, was promoted to Chief
Accounting Officer on March 14, 2018 and will serve as the
Company’s principal financial officer and assume responsibility for
finance, tax and treasury.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
nicknamed C1. The C1 microorganism, which enables the development
and large-scale manufacture of low cost proteins, has the potential
to be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of using these technologies in the
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Contact:
Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
Phone: 561-743-8333
Email: memalfarb@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2023 to Apr 2024